Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma

Pazopanib is a multi-targeted tyrosine kinase inhibitor, which is indicated for use in patients with advanced renal cell carcinoma or advanced soft-tissue sarcomas. Although rare, interstitial lung disease has been reported as among the adverse sequelae of pazopanib therapy. We report the case of a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMJ Case Rep
Asıl Yazarlar: Harada, Yukinori, Kakimoto, Shintaro, Shimizu, Taro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2020
Konular:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7348321/
https://ncbi.nlm.nih.gov/pubmed/32641305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-235177
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller